Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

Contributed by: PR Newswire

Tags

HANSA-SERB-Agreement

More Like This

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million

SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update

Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results

Hansa Biopharma Year-end report January-December 2023

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients